Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy

Figure 2

Growth curves of primary B16 melanomas. Experimental conditions and statistical analyses of (a), (b), (c) and (d) are identical to those of Protocol number 1. (a) Growth curve of B16F1 melanoma cells treated with NPrCAP/M alone without heat (𝑛=10) and with heat by AMF exposure (𝑛=10) at days 6, 8, and 10. These two groups showed a significant growth inhibition compared to that of control naive mice (𝑛=10) by Dunnet’s test (𝑃<.01). Importantly, there is no significant difference between the two groups with and without AMF exposure. (b) Growth curve of B16F1 melanoma cells treated with magnetite alone (𝑛=10) and NPrCAP/M alone without AMF exposure (𝑛=10). Mice with magnetite alone did not show any growth inhibition whereas NPrCAP/M alone resulted in a significant growth inhibition of primary melanoma (𝑃<.01). (c) Comparison of growth inhibition of B16F10 primary melanomas after treatment with NPrCAP/M with AMF exposure. Compared to control naive mice (𝑛=10) transplanted with B16F10 cells without any treatment, those mice (𝑛=10) with NPrCAP/M plus AMF exposure showed a significant growth inhibition of primary B16F10 melanomas with a similar degree to that of B16F1 melanoma (Figure 2(a)) (𝑃<.01 by Dunnet’s test). (d) Comparison of the growth inhibition of B16F10 secondary, re-challenge melanoma. The mice (𝑛=10) with NPrCAP/M plus AMF exposure showed a marked growth inhibition compared to control naive mice without any treatment (𝑛=10).